Importance of dose intensity in neuro-oncology clinical trials: Summary Report of the Sixth Annual Meeting of the Blood-Brain Barrier Disruption Consortium

Nancy D. Doolittle, Clarke P. Anderson, W. Archie Bleyer, J. Gregory Cairncross, Timothy Cloughesy, Stephen L. Eck, Paul Guastadisegni, Walter A. Hall, Leslie L. Muldoon, Sunil J. Patel, David Peereboom, Tali Siegal, Edward A. Neuwelt

Research output: Contribution to journalArticle

25 Scopus citations

Abstract

Therapeutic options for the treatment of malignant brain tumors have been limited, in part, because of the presence of the blood-brain barrier. For this reason, the Sixth Annual Meeting of the Blood-Brain Barrier Disruption Consortium, the focus of which was the "Importance of Dose Intensity in Neuro-Oncology Clinical Trials," was convened in April 2000, at Government Camp, Mount Hood, Oregon. This meeting, which was supported by the National Cancer Institute, the National Institute of Neurological Disorders and Stroke, and the National Institute of Deafness and Other Communication Disorders, brought together clinicians and basic scientists from across the U.S. to discuss the role of dose intensity and enhanced chemotherapy delivery in the treatment of malignant brain tumors and to design multicenter clinical trials. Optimizing chemotherapy delivery to the CNS is crucial, particularly in view of recent progress identifying certain brain tumors as chemosensitive. The discovery that specific constellations of genetic alterations can predict which tumors are chemoresponsive, and can therefore more accurately predict prognosis, has important implications for delivery of intensive, effective chemotherapy regimens with acceptable toxicities. This report summarizes the discussions, future directions, and key questions regarding dose-intensive treatment of primary CNS lymphoma, CNS relapse of systemic non-Hodgkin's lymphoma, anaplastic oligodendroglioma, high-grade glioma, and metastatic cancer of the brain. The promising role of cytoenhancers and chemoprotectants as part of dose-intensive regimens for chemosensitive brain tumors and development of improved gene therapies for malignant gliomas are discussed.

Original languageEnglish (US)
Pages (from-to)46-54
Number of pages9
JournalNeuro-Oncology
Volume3
Issue number1
DOIs
StatePublished - Jan 2001

ASJC Scopus subject areas

  • Oncology
  • Clinical Neurology
  • Cancer Research

Fingerprint Dive into the research topics of 'Importance of dose intensity in neuro-oncology clinical trials: Summary Report of the Sixth Annual Meeting of the Blood-Brain Barrier Disruption Consortium'. Together they form a unique fingerprint.

  • Cite this

    Doolittle, N. D., Anderson, C. P., Bleyer, W. A., Cairncross, J. G., Cloughesy, T., Eck, S. L., Guastadisegni, P., Hall, W. A., Muldoon, L. L., Patel, S. J., Peereboom, D., Siegal, T., & Neuwelt, E. A. (2001). Importance of dose intensity in neuro-oncology clinical trials: Summary Report of the Sixth Annual Meeting of the Blood-Brain Barrier Disruption Consortium. Neuro-Oncology, 3(1), 46-54. https://doi.org/10.1093/neuonc/3.1.46